"The Effect of Stellate Ganglion Block in Severe Brain Injury"
NCT ID: NCT04208477
Last Updated: 2024-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2021-11-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of the Stellate Ganglion Block on the Retinal Microcirculation
NCT06797752
Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage
NCT04512859
Stellate Ganglion Block and Cerebral Vasospasm
NCT04691271
Stellate Ganglion Block as Adjuvant Therapy to ca Channel Blocker
NCT04100824
The Utility of Thromboelastography in Traumatic Brain Injury
NCT04524637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stellate ganglion blockade in patients with moderate and severe brain damage:
1. Increases the diameter of the brain arteries and blood flow through the brain
2. Do not interfere with intracranial pressure
3. Reduces aseptic inflammatory reaction of the damaged brains measured by IL-6 and reduces damage of the brain tissue measured by protein S100B (S100B), neuron specific enolase (NSE) and glial fibrillary acidic protein (GFAP).
Study design and method description
The study will include 40 subjects of both sexes (18-70 years old) with moderate and severe head injury who will be treated surgically and/or conservatively at the Intensive Care Center (CIT) of the Department of Anesthesiology and Intensive Care UKC Ljubljana. The study will include patients who underwent computed tomography angiography of the brain (CTA) and received an intra-parenchymal intracranial pressure monitor electrode (ICP) at admission to the UKC Ljubljana Emergency Center or during CIT treatment. After primary conservative or surgical care, the subjects will be transferred for further treatment at CIT. Subjects will be sedated and mechanically ventilated. To maintain target cerabral perfusion pressure (CPP), the investigators will give an infusion of noradrenaline as needed. The study will not include subjects with primary decompression craniectomy and radiological signs of progression of intracranial hematomas, subjects in a barbiturate coma, and subjects with a norepinephrine dose greater than 0.2 mcg/kg/min. The study will not include pregnant women, children, patients with known hypersensitivity to iodine contrast media and local anesthetics, and patients with poor renal function (estimated glomerular filtration below 30ml / min / 1.73m2).
The research will be conducted during patient treatment at CIT. The investigators will begin the investigation after positive positive opinions from the Medical Ethics Commission of the Republic of Slovenia, and obtained written consent form patient's family members or official legal representatives.
The effect of BSG on brain blood flow and the diameter of brain vessels will be evaluated by CTA, PCT, TCD.
BSG will be done during the first week after admission at CIT on the same patient's side of the ICP position. One hour after BSG, control CTA in PCT will be done. TCD od the left and right middle brain artery (ACM) will be performed one hour before and after BSG.
TCD will be used to measure the rate of blood flow through ACM in systole-Vs in diastole-Vd and pulsatility index (PI). The investigators will compare Vs, Vd values and PI before and after BSG.
Possible changes in the diameter of large brain vessels after BSG will be compared between CTA done at the emergency center or during CIT treatment and a control CTA after BSG. For standard diameter measurement sites, the investigators will take the middle third of M1 and the proximal part of the M2 segment of the ACM, the middle third of the A1 and A2 segments of the anterior brain artery (ACA), the P1 segment and the first part of P2 segment of the posterior brain artery (ACP), the terminal part of the interior carotid artery (ACI), the middle third of the intradural part of the vertebral artery and middle third of the basilar artery. Changes in the diameter of the brain vessels will be presented numerically and descriptively.
With PCT-produced color maps beside qualitative evaluation od the possible changes of the brain blood flow on the left and right brain hemisphere after BSG, the investigators will also evaluate changes in regional brain blood volume (rCBV), regional brain blood flow (rCBF), mean transition time (MTT). Outside the contusion regions, the investigators will mark the region of interest (ROI) of 500 mm2 for ACA, ACM and ACP perfusion areas. Siemens SyngoVia software will be used.
PCT and CTA will be done by the helical CT tomogram (Somatom, Siemens, Erlangen, Germany). A 40 ml non-ionic low-osmolar iodine contrast medium, 370 mg/ml iopromide (Ultravist; Bayer HealthCare, Berlin, Germany) will be used. It will be injected at a flow rate of 5 ml/s into a cubital vein. Perfusion imaging will be initiated 7 seconds after the injection of contrast.
Blood samples for the determination of IL6, NSE, S100B in GFAP will be drawn from the right external jugular vein and peripheral artery (radial or femoral artery) one hour before and 1, 6, 12, 24 hours after BSG. The investigators will compare IL6, NSE, S100B, GFAP values in venous blood from right jugular vein before v after BSG. A comparation of the values of IL6, NSE, S100B, GFAP in venous blood from the right internal jugular vein in arterial blood taken from the peripheral artery will be done as well. Blood samples will be sent for analysis to the central laboratory of UKC Ljubljana.
Brain oxygenation will be measured with a non-invasive method on both fronts using Near Infrared Spectroscopy (NIRS). NIRS measurement values will be measured immediately before BSG and within 5, 10, 15, 20, 25 and 30 minutes after BSG.
BSG will be done ipsilaterally to the inserted ICP electrode. BSG will be done under ultrasound control at the C6-C7 level, with a lateral approach with a Stimulplex Ultra 360 5cm needle (B.Brown). A 6-15 MHz high frequency probe will be used. BSG will be done always by the same anesthesiologist. The injection site and the ultrasound probe will be aseptically prepared. The ultrasound probe will be placed transversely to the neck axis at the height of the sixth cervical vertebra. After preliminary verification of the needle tip position over the long cervical muscle and under the prevertebral fascia and after negative aspiration, 8 ml of 0.5% levobupivacaine will be injected. Because het investigator's subjects will be sedated, onset of the BSG will be confirmed 10 minutes after the blockade, by the onset of three signs of Horner's syndrome (ptosis, myosis, enophthalmus, anhydrosis, conjunctival hyperemia): enophthalmus, anhydrosis, conjunctival hyperemia.
ICP in CPP will be continuously measured before and after BSG. The data will be analyzed in graphical display using IBM SPSS Statistics statistical programs, ver. 25 and Microsoft Excel. The variables will be presented as mean values with standard deviation or as median with interquartile range. Using the paired t-test, the investigators will compare the average values of the sample's numerically variables. Significant differences will be defined as p\<0,05.
Expected results
When investigating the effect of BSG on the brain circulation and inflammatory response in subjects with moderate and severe brain damage, the investigators expect a significant increase in the diameter of the large brain arteries, and thus a positive effect of BSG on the brain circulation of the injured brain (decreased mean blood transition time, increased blood volume in the brain, and increased blood flow through the brain). The investigators estimate that BSG will not change the intracranial pressure. The investigators expect NIRS values to be significantly higher after the blockade than before the blockade. Due to the positive effects of BSG on the aseptic inflammatory response of non-injured brain, BSG is expected to have the same effect in the injured brain. The investigators also expect BSG will decrease the concentration of biochemical indicators of inflammation and damage to neurons and glia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BSG patients
one site blockade of the stellate ganglion
Ultrasound guided one site blockade of the stellate ganglion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
one site blockade of the stellate ganglion
Ultrasound guided one site blockade of the stellate ganglion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who underwent computed tomograply angiography of the brain (CTA) at admission to the UKC Ljubljana Emergency Center or during CIT treatment
* patients with intra-parenchymal intracranial pressure monitor electrode (ICP) installed
Exclusion Criteria
* radiological signs of progression of intracranial hematomas
* barbiturate coma
* patients with a norepinephrine dose greater than 0.2 mcg/kg/min
* pregnant women
* children
* known hypersensitivity to iodine contrast media and local anesthetics
* poor renal function (estimated glomerular filtration below 30ml / min / 1.73m2).
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ivan Kostadinov
asist Ivan Kostadinov, dr.med.EDRA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ivan Kostadinov
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kostadinov I, Avsenik J, Osredkar J, Jerin A, Gradisek P. Effect of stellate ganglion block on brain hemodynamics and the inflammatory response in moderate and severe traumatic brain injury: a pilot study. Reg Anesth Pain Med. 2025 Feb 19:rapm-2024-106185. doi: 10.1136/rapm-2024-106185. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMCLjubljana Stellate
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.